We describe a novel Bayesian method for estimating protein concentration and phosphorylation site occupancy ratios from mass spectrometry experiments. Our variance model assigns standard deviations to all quantitative ratios, even when only a single peptide is observed, increasing the number of quantifiable observations in a sample compared to conventional methods. We further demonstrate the application of this method using a dataset investigating the impact of the PRKAR1A-RET gene fusion in immortalized thyroid cells.
tial amount of data points. This effect is exacerbated when considering analysis of post-translational modifications, which are usually measured as a single peptide, as opposed to proteins that are measured as the aggregate of multiple peptides. Moreover, uncertainties can only be measured reliably when enough measurements are available and are often ignored altogether. In order to provide accurate uncertainties on the measurement of protein and phosphorylation site ratios, we developed a Bayesian noise model of the experimental and instrumental errors, and derived a likelihood expression of protein concentration and phosphorylation site occupancies, sampled using a Bayesian Markov Chain Monte Carlo approach. Through the propagation of effective measurement numbers this model can more accurately derive significance from a low number of observations. In order to model log ratios (sample versus control) of protein concentration (c) and occupancy of posttranslational modification sites (o and o representing the proportion of proteins where the site is modified in the sample and control, respectively), we established the following formula, which models the average ratio (µ) of a peptide i (with potentially multiple post-translational modifications) as a function of the parameters c,ō andō :
where I is and t is are indicator matrices specifying which sites are covered and modified, respectively.
Together with an appropriate noise model, this function could be sampled and compared to we calculated peptide log ratios to the 12.5 fmol/µg sample, peptide standard deviation and the number of effective observations ( Figure 1E ). Samples with less than 2.5 fmol/µg were discarded as they contained very few identified UPS1 peptides. We then randomly generated 100 artificial proteins from the remaining peptides with random Gaussian average ratios and sampled these with the Monte Carlo likelihood model, the results of which are shown in Figure 1F . The model produced relatively conservative estimates of the true ratios, and ratios with large uncertainties were drawn towards 0.
Overall the correlation of known to predicted concentration ratios was 0.938 validating the accuracy of our method. To further validate our model we reanalyzed previously published phosphoproteomic analyses investigating epidermal growth factor stimulation 2 and insulin signaling 3 . In all cases the Monte Carlo model was able to quantify, with measures of uncertainty, more proteins and phosphorylation sites than conventional methods, with the most significant increases seen in sparse data with few replicates ( Figure S1 ).
In order to demonstrate the applicability of this method for analyzing complex large-scale data,
we investigated the effects of the PRKAR1A-RET chromosomal translocation in immortalized thyroid cells using global phospho-proteomics. Fusion kinases are commonly observed in both blood and solid tumors in cancer patients, and many have been shown to be recurrent 4 . The best known of these is the BCR-ABL fusion, a driver for chronic myeloid leukemia, which led to the development of the first targeted therapy for cancer: Imatinib/Gleevac 4 . Given that gene fusions have the potential to be relevant therapeutic targets it is perhaps surprising that the underlying signaling network alterations driving cancer progression are still only described, to some degree, for a handful of gene fusions. It would seem likely that mass spectrometry analysis of fusion-induced signaling network rearrangements could go some way towards filling this void. However, a limitation to such studies is that often peptides 'fall out' of the analysis due to limitations of instrumentation and sample preparation. Thus, data analytical methods that can help capture low-stoichiometry events are critically needed.
The PRKAR1A-RET fusion kinase has been observed in multiple thyroid cancer patients retaining the regulatory and cyclic NMP binding domains of the PRKAR1A protein on the N-terminus and the full tyrosine kinase domain from the RET kinase on the C-terminus 5 . In order to create the most physiologically relevant model we recreated this fusion using CRISPR-Cas9 in thyroid cells. As primary human epithelial cells senesce after only a few divisions in culture we used SV-40 immortalized thyroid cells (Nthy-ori 3-1 6 ) that are suitable for large-scale mass spectrometry experiments, but have low colony formation ability and are non-tumorigenic in mice. Following expression of the PRKAR1A-RET fusion, cells were tested in an anchorage-independent growth assay. Strikingly, we observed a significant increase in colony formation in the cells expressing the PRKAR1A-RET rearrangement compared to control cells ( Figure S1 ). This would suggest that the engineered fusion event, either directly or indirectly, induced malignant transformation in our cell model. Mass spectrometry analysis of the cells and colonies expressing the PRKAR1A-RET gene fusion identified 1 985 159 peptides, 248 536 of which were phosphorylated, over the entire presented dataset. This corresponded to 5759 unique proteins and 11 435 unique, high-confidence, phosphorylation sites; 5672 of the unique proteins were observed with two or more peptides. From these data our Monte Carlo model was able to quantify ratios, calculated from sample thyroid cells expressing the PRKAR1A-RET fusion to control thyroid cells expressing Cas9 protein alone, for 94% of the observed proteins (5411) and 70% of the observed phosphorylation sites (8032), significantly more than was possible using conventional analysis methods (MaxQuant).
We noted that a remarkably similar phosphorylation site occupancy signal was observed in each fusion-expressing cell line (Figure 2 ), suggesting that the changes to signaling networks driven by this chromosomal rearrangement are highly conserved. Given that the cells grown in colony formation assays were also distinct from fusion-kinase expressing cells at the level of both the proteome and phospho-proteome this would suggest that additional signaling network rearrangements occurred driving tumorigenesis in cells that displayed anchorage-independent growth. In particular we noted that the concentration of PRKAR1A was found to be downregulated in the transformed cells relative to colonies formed without the fusion construct. In order to determine which cellular processes were regulated following PRKAR1A-RET fusion functional annotations were assigned using the hallmark gene set collection of the Molecular Signature Database 7 , based on coherently expressed genes representative of biological processes 8 . Processes that were significantly enriched in cells expressing the PRKAR1A-RET fusion are shown in Figure S2 and Table S1 . In particular, we noted that in cells expressing the PRKAR1A-RET fusion there was enrichment for signaling via PI3K-AKTmTOR, which has previously been shown to affect cell proliferation, viability and iodide uptake in thyroid cells 9 , and Myc, which is known to be involved in the majority of human cancers and leads to the acquisition of hallmark cancer characteristics such as uncontrolled proliferation 10 . Interestingly we observed that additional signaling pathways were modulated in the colonies expressing PRKAR1A-RET, including P53, alterations in which are known to contribute to carcinogenesis in thyroid tissue 11 . Given the significant number of additional phosphorylation sites quantified by the Monte Carlo model (most likely due to the sparcity of the data, which has fewer biological replicates than the other analyzed datasets) we used DAVID 12 to determine whether there was enrichment of specific signaling pathways which were only quantified by Monte Carlo analysis. We observed significant enrichment of proteins associated with spliceosome (P=0.0026) and glycolysis (P=0.018) pathways, both of which are considered relevant targets for novel cancer therapeutics 13, 14 . Given this, and the known importance of kinases in cancer 15 in general, it would seem highly likely that the additional information provided by the Monte Carlo model would aid biological analysis of the role of the PRKAR1A-RET fusion kinase.
These data demonstrate the ability of our model to estimate protein concentration and phosphosite occupancies and to provide an accurate estimate of the uncertainty of those parameters. We believe that a more rigorous modeling of uncertainties is a critical step towards more precise models, which will allow more informed interpretation of quantitative mass spectrometry data. While the model presented here is based on peptide ratios, this method could also be applied to model peptide intensities. This would enable the modeling of additional missing data points due to intensities that are below the detection threshold of the mass spectrometer. Similar models could be used for datasets generated using other quantification methods such as TMT or SILAC. 
Determination of targeted breakpoint location
The empirically observed breakpoint of the translocation event was verified using COSMIC 16 and ChiTars 17 and the introns selected by following the principle of last observed-and first observed exons given several documented cases of the same translocation, with varying numbers of exons detected in the partner genes. Only one combination of introns targeted for CRISPR-Cas9-mediated cleavage was retained, using the intron following the last seen exon of the head partner and the intron preceding the first observed exon of the tail moiety.
CRISPR sgRNA target selection and cloning
All SpCas9 Protospacer Adjacent Motif (PAM) sites within selected introns were scored using the method described by Doench et al. 18 . The two top-scoring guide sequences were retained for each translocation partner. A 'G' was prepended to the guide sequence (GX20 sgRNA), with the benefit of diminishing off-targets at the cost of cutting efficiency 18 . Top-scoring guide sequences were verified by submission to the CRISPR Design webtool (http://crispr.mit.edu/) 19 . Selected sgRNAs were verified with the updated off-target prediction algorithm GUIDE-seq 20 . The pLX-sgRNA vector was digested with Xba1, Nde1 for 2 hrs at 37
• C, ran on a 0.5% agarose gel followed by gel extraction and purification. The DNA digest was further used to clone a new vector allowing for facile insertion of sgRNA oligonucleotides via Gibson reactions. In order to select for successful transduction of the second sgRNA, the vector was further modified to replace the blasticidin resistance with hygromycin.
HEK-293 infection 2x10 6 HEK-293T packaging cells were seeded in a 75cm 2 cell culture flask in growth medium without antibiotics. The following day, cells were transfected with pCMV-VSV-G, psPAX2, and pCW-Cas9 vectors using MirusBio TransIT-LT1 transfection reagent. After 24 hours medium was removed and fresh medium containing 10mg/ml bovine serum albumin was added. 24 hours later medium was harvested and residual cells were removed by filtration.
Viral pCW-Cas9 transduction
Nthy-ori 3-1 cells were seeded at 300 000 cells/well in a 6-well plate. The following day, protamine sulfate was added to flasks to a final concentration of 8 µg/ml and cells were transduced with the 
Viral modified pLX-sgRNA transduction
Medium containing viral sgRNA vectors was harvested as previously described for each individual sgRNA. 1x10 6 Thy-Cas9 cells were seeded per 25 cm 2 cell culture plate. The following morning harvested medium was added to growth medium in increasing volumes, at equal volumes between the two sgRNAs of a given combination. Cells were split twice and selected for 14 days in medium supplemented with 0.8 µg/mL puromycin, 10 µg/mL blasticidin or 200 µg/mL hygromycin. The condition with lowest viral volume mediating resistance was retained for further experiments.
Cas9 expression induction
Doxycycline at a final concentration of 1 µg/mL was administered for 1 week to 4x10 5 cells seeded in a 100mm tissue culture dish. Doxycycline-containing medium was refreshed after 4 days. Immediately thereafter individual clones were generated via single cell cloning and expanded. 
Translocation detection PCR

Anchorage-independent growth assay
Transformation was verified using a soft agar colony formation assay 21 . 6-well tissue culture plates were coated with growth medium containing 1% agarose, and triplicate dishes were inoculated with 10 000 or 2000 cells suspended in RPMI-1640 medium containing 0.8% agarose and 15% fetal bovine serum, for counting and colony picking, respectively. Colony formation was assessed after 2 weeks. Image analysis was performed using ImageJ, with plugins ColonyArea 22 and ColonyCounter (https://imagej.nih.gov/ij/plugins/colony-counter.html).
Mass spectrometry lysis and sample preparation Enriched peptides were subjected to a final C18 clean-up prior to data acquisition. All samples were processed as technical duplicates.
MS data acquisition
All spectra were acquired on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) operated in data-dependent mode coupled to an EASY-nLC 1200 (Thermo Fisher Scientific) liquid chromatography pump and separated on a 50cm reversed phase column (Thermo, PepMap RSLC C18, 2uM, 100 AA, 75umx50cm). Proteome samples (non-enriched) were eluted over a linear gra- 
Spectral search and quantification
All label-free raw data were searched using MaxQuant 1.5.1. 
UPS1 benchmark
Data was downloaded from ProteomeXchange (PXD001819) and searched with MaxQuant 1.5. 
Post-spectral search data processing
Mass spectrometry spectra were identified by MaxQuant 28 and assigned a sequence and modification status. This was then used to identify the quantitative information obtained from the sequence of MS 1 spectra over chromatography time, in the form of an Extracted Ion Chromatogram (XIC) measurement of intensity. We then investigated the XIC intensity of a modified peptide with a known sequence, in the corresponding sample and mass spectrometry run (and raw file). We extracted quantitative information regarding ion intensities from the evidence.txt file. We filtered out peptides that were associated with multiple identifications in the msms.txt file, had a score < 40, were identified in the reverse database or came from known contaminants. We also filtered all modified peptides with a localization probability < 0.9.
Calculating average intensity
A peptide P could be observed in multiple XIC in a single run. We defined the aggregated intensity of peptide P p,s,r , where p was the sequence of the peptide, s was the sample and r was the run, as:
When we observed the peptide in multiple replicates we further summarized the mean intensity I:
For normalization purposes we also calculated an average intensity over a mass spectrometry run.
However because intensities are not normally distributed but approximately follow a log-normal distribution, the log intensities were summarized instead thusly:
Ratios calculation
We defined the log-ratio of a peptide concentration from a sample s to the control s = u as:
r ps = f (I ps , I p(s=u) ) (5) where I p(s=u) is the intensity of a peptide p in the control sample u.
Error propagation
In order to propagate the standard deviation σ x , when calculating a log-ratio by a pair of intensities we applied the general Gaussian error propagation, which reads for a function f(x,y) depending on the two variables x and y: (6) and subsequently in our case for the log-ratio (where the minus is introduced by the partial derivative of the log-ratio to the denominator):
Cov(I ps , I p(s=c) )
Because we considered the replicates to be independent from each other, we could further simplify the covariance term:
Normalization
As different amounts of sample could be injected into the mass spectrometer, and because the chromatography is not expected to be identical in each experiment, different experiments were scaled before they were compared using a correction factor based on the average intensity (geometric mean) in order to account for the potential impact of very high intensity peptides within a sample:
And the correction factor S could be expressed as:
Peptide intensities could thus be corrected, and a normalized intensity N calculated, as follows:
Summarization worked as described above by replacing I p,s,r with N p,s,r .
Variance model
In order to get a baseline estimate of the peptide variance, we established a Bayesian variance model. We modeled the behaviour of the standard deviation of σ r ps as a function of abs(r ps ). Data was split into bins containing at least 600 data points each along abs(r p s), and for each bin we fit 1/σ 2 to a Γ distribution with shape parameter a and rate b. We observed that a ≈ 1, and
Likelihood function
The likelihood function was calculated from a given phosphorylation site s, the set of phosphorylation sites S i for sequence i, the total number of modifiable sites S and the occupancy ratio o s = p s /c on site s, which is the fraction of peptide that is modified. Assuming o s values would be mutually independent, the log concentration ratio, µ i , was given by:
where c is the protein log concentration ratio between the sample and the reference,ō andō are the collection of occupancy ratios for the sample and the reference respectively, and t is are indicator variables signifying whether site s is modified (1) represented the collection of expected values. Then P (z|μ) = i P (z i |µ i ) where each factor is a non-standardized t distribution. Defined for convenience as:
Consequently the likelihood function was given as:
L(c,ō,ō ) = log P (z|μ(c,ō,ō ))
Markov Chain Monte Carlo sampling
We optimized the function for each protein separately with Bayesian Markov Chain Monte Carlo simulations. We used a Jeffrey prior on o s with α 1 = α 2 = 1 2 and an exponential prior with λ = 2 on c.
2% of the proposed moves were drawn from the prior distribution of the parameters as described above. Standard moves were as c t+1 = c t + N (λ = 0, σ = 0.05) for the concentration and o s,t+1 = o s,t +N (λ = 0, σ = k) for occupancies, with a standard deviation corrected to propose smaller moves when o s approaches 0 or 1.
In addition, all moves that would result in o s < 10 −5 or o s > 1 − 10 −5 were automatically rejected.
In order to ensure a good sampling of the likelihood, we used the effectiveSize Coda R package 
We rounded f (n p ) up to the next power of 10 to get the final number of iterations n c . Chains with n c > 10 9 were re-initialized after 10 9 iterations. We used a burn-in time of 30% and saved the state of the chains 7 * 10 3 times as output. Proteins with at least one chain with effectiveSize smaller or equal to 100 were repeated with 10 times more iterations.
Data and software availablility 
Γ(rate, shape) p H (i), where p L,H (i) is the probability of peptide i in the L and H MS-2 analysis, respectively. If only one MS-2 spectra has been observed, say for L-sample. we can calculate the expected effective number of observations for the top scoring peptide i top according to the observed p 
